Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial

Niklas Dyrby Johansen(Gentofte Hospital), Tor Biering‐Sørensen(Copenhagen University Hospital), Palle Valentiner‐Branth(Statens Serum Institut), Lars Køber(University of Copenhagen), Gunnar Gislason(Copenhagen University Hospital), Jens‐Ulrik Stæhr Jensen(University of Copenhagen), Sandrine Samson(Sanofi (France)), Scott D. Solomon(Brigham and Women's Hospital), Carsten Schade Larsen(Emory Healthcare), Daniel Modin(University of Copenhagen), Tyra Grove Krause(Statens Serum Institut), Martin Landray(Gentofte Hospital), Pradeesh Sivapalan(Gentofte Hospital), Camille Salamand(Sanofi (France)), Joshua Nealon(Sanofi (France)), Lasse S. Vestergaard, Brian Claggett(National Heart Lung and Blood Institute)
Pilot and Feasibility Studies
April 21, 2022
Cited by 24


Related Papers